<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01725906</url>
  </required_header>
  <id_info>
    <org_study_id>201202068MIC</org_study_id>
    <nct_id>NCT01725906</nct_id>
  </id_info>
  <brief_title>Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication</brief_title>
  <official_title>Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aimed to compare the efficacy of genotypic resistance guided sequential therapy vs.
      empiric therapy in the third line therapy. Factors affecting the eradication rates, including
      the antibiotic resistance, CYP2C19 polymorphism, CagA and VacA status will also be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary aim of this study is to compare the regimens selected using either one of the
      method (1) genotypic resistance guided versus (2) medication history guided therapy. (rather
      than to compare the efficacy of any drugs).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication rate after third line rescue therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Primary End Point: Eradication rate will be evaluated according to Intent-to-treat (ITT) and per-protocol (PP) analyses.
(genotypic resistance versus empirical therapy) Urea breath test will be used to determine the eradication status</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>eradication rates in subgroup analysis by antibiotic resistance and regimen</measure>
    <time_frame>8 weeks</time_frame>
    <description>eradication rate in subgroup analysis according to antibiotic resistance and treatment regimen</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Self Efficacy</condition>
  <arm_group>
    <arm_group_label>Empirical therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>selection of antibiotic according to medication history</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>selection of antibiotics according to genotypic resistance</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>empirical therapy</intervention_name>
    <description>Nexium (esomeprazole), 40mg, bid, 14 days, plus
Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus
Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs
Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14</description>
    <arm_group_label>Empirical therapy</arm_group_label>
    <other_name>selection of antibiotics according to medication history</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genotypic resistance guided therapy</intervention_name>
    <description>Nexium (esomeprazole), 40mg, bid, 14 days, plus
Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus
Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs
Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14</description>
    <arm_group_label>Genotypic resistance guided therapy</arm_group_label>
    <other_name>selection of antibiotic according to genotypic resistance</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged greater than 20 years who have persistent H. pylori infection after at
             least two treatments and are willing to receive third line rescue regimens are
             considered eligible for enrollment.

        Exclusion Criteria:

          -  Patients will be excluded from the study if any one of the following criteria is
             present: (1) children and teenagers aged less than 20 years, (2) history of
             gastrectomy, (3)gastric malignancy, including adenocarcinoma and lymphoma, (4)
             previous allergic reaction to antibiotics (Amoxicillin, Klaricid, Cravit) and prompt
             pump inhibitors (esomeprazole), (5)contraindication to treatment drugs, (6) pregnant
             or lactating women, (7) severe concurrent disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jyh-Ming Liou</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jyh-Ming Liou, MD</last_name>
    <phone>+886223123456</phone>
    <phone_ext>63541</phone_ext>
    <email>dtmed046@pchome.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan Universtiy Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jyh-Ming Liou, MD</last_name>
      <phone>+886972651883</phone>
      <email>dtmed046@pchome.com.tw</email>
    </contact>
    <investigator>
      <last_name>Ming-Shiang Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Yun-Lin County</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chieh-Chang Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>November 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2012</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Taiwan University Hospital</investigator_affiliation>
    <investigator_full_name>National Taiwan University Hospital</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>genotypic resistance guided therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

